I may be mistaken, but I've always thought the current studies with small sample sizes were just to get the CLIA phase going. The data gathered through the use of Lympro in CLIA labs will eventually be used to gain FDA approval down the road. CLIA testing is where the large sample size data will come from. Isn't that the reason they went this route? Faster and cheaper. Please correct me if I'm wrong, but that's what I thought all along.